Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed the second and final tranche (the "Second Tranche") of its previously announced private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 4,005,408 Units at a price of $0.30 per Unit (the "Offering Price") for aggregate gross proceeds of $1,201,622.40. In total, the Company issued an aggregate of 5,425,608 Units under the Offering for aggregate gross proceeds of $1,627,682.40.
Who to call at INNOCAN PHARMA Corp, and when
A new round usually means INNOCAN PHARMA Corp is about to hire and buy. The teams that reach out first get the meeting.
An alert the day INNOCAN PHARMA Corp raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at INNOCAN PHARMA Corp, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at INNOCAN PHARMA Corp. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
INNOCAN PHARMA Corp
Location
1015, 926 - 5 AVENUE SW
Herzliya, Tel Aviv, Israel
About
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment INNOCAN PHARMA Corp raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
HerzliyaBiotechnologyHealth CarePharmaceuticalpharmaceuticals